精锋医疗正式登陆港交所：市值228亿港元，手术机器人领域龙头企业

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") is the first company in China and the second globally to commercialize both multi-port and single-port surgical robots, marking a significant milestone in the surgical robotics industry [2][4]. Group 1: IPO Details - Precision Medical officially listed on the Hong Kong Stock Exchange on January 8, 2026, under the stock code "2675" [2]. - The company issued a total of 27,722,200 H shares, with the Hong Kong public offering being oversubscribed by 1,091.94 times and the international offering by 25.18 times [2]. - The IPO raised approximately HKD 1.199 billion at an issue price of HKD 43.24 per share, with the stock opening at HKD 59, giving it a market capitalization exceeding HKD 22.8 billion [2]. Group 2: Technological Innovation - Precision Medical focuses on the independent research and development of high-end minimally invasive surgical equipment, aiming to upgrade surgical procedures towards precision, minimally invasive, and intelligent solutions [4]. - The company has developed a comprehensive product lineup covering multi-port, single-port, and natural orifice surgical robots, achieving autonomy in several key technological areas [4]. - As of now, Precision Medical holds 734 authorized and pending patents globally, establishing a robust technical system that encompasses research and development, manufacturing, clinical application, and continuous iteration [4]. Group 3: Clinical Application and Growth - Over 12,000 surgeries have been performed using the multi-port surgical robot, and more than 2,000 surgeries with the single-port robot, indicating a stable growth in clinical usage and integration into standard surgical pathways [5]. - The company reported approximately CNY 149 million in revenue for the first half of 2025, representing a nearly 400% year-on-year increase, with a gross margin of about 62.8% [4][5]. - Precision Medical plans to leverage its IPO as a new starting point to enhance research and development in advanced technologies, complex procedures, and remote surgeries, while expanding production capacity and global market reach [5]. Group 4: Market Position and Future Outlook - Investors such as Qiming Venture Partners and Sequoia China view Precision Medical's successful IPO as a landmark achievement in breaking international monopolies and leading the development of China's surgical robotics industry [6][7]. - The company is expected to continue expanding its clinical applications and global market presence, contributing significantly to the high-quality development of China's high-end medical equipment industry [6][7]. - Precision Medical is recognized for its rapid product iteration and strong market acceptance, positioning itself as a leading player in the surgical robotics sector both domestically and internationally [6][7].